Orexigen Therapeutics (OREXQ) Stock Price, News & Analysis

Company Overview

Orexigen Therapeutics, Inc. was a biopharmaceutical company focused on developing and commercializing treatments for chronic weight management and obesity-related conditions. The company’s research centered on therapies designed to affect appetite and reward pathways in the brain.

Orexigen’s principal product was Contrave, an extended-release combination of naltrexone and bupropion. The U.S. Food and Drug Administration approved Contrave in 2014 for chronic weight management in adults who are obese or overweight with at least one related medical condition. Outside the United States, the product was known as Mysimba and was commercialized through licensing and regional partnerships.

Orexigen entered bankruptcy proceedings in 2018 after experiencing financial and commercial difficulties. Its assets and product rights were subsequently subject to restructuring and sales, and the company no longer operates as an active biopharmaceutical business in the manner of its earlier corporate history. Michael Narachi served as the company’s chief executive officer during a significant portion of its commercialization period.

Key Stats

• Today's Range: $0.0027 to $0.0053
• 50-Day Range: $0.0053 to $0.0053
• 52-Week Range: $0.00 to $0.16
• Volume: 60,300 shs
• Average Volume: 80,439 shs
• Market Capitalization: $100.10 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:OREXQ
• CIK: 1382911
• Web: www.orexigen.com
• Phone: 858-875-8600
• Fax: N/A
• Employees: 132
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $33.71 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,887,000
• Free Float: N/A
• Market Cap: $100.10 thousand
• Optionable: Not Optionable
• Beta: 4.98